Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

WF-210 compound MeSH Supplementary Concept Data 2025


MeSH Supplementary
WF-210 compound
Unique ID
C000628065
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C000628065
Entry Term(s)
N'-(4-((2-(benzo(d)(1,3)dioxol-5-ylmethyl)thiazol-4-yl)methoxy)-2-hydroxybenzylidene)-2-(4-((3-(4-((4-fluorophenoxy)methyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)piperazin-1-yl)acetohydrazide
WF-210
Pharm Action
Enzyme Activators
Registry Numbers
0
Heading Mapped to
*Benzylidene Compounds
*Dioxoles
*Hydrazines
*Oxadiazoles
*Piperazines
Frequency
1
Note
a procaspase-3 activating compound derived from procaspase activating compound-1 (PAC-1 compound)
Source
Eur J Pharmacol. 2018 Feb 15;821:29-38.
Date of Entry
2018/08/24
Revision Date
2018/08/24
WF-210 compound Preferred
N'-(4-((2-(benzo(d)(1,3)dioxol-5-ylmethyl)thiazol-4-yl)methoxy)-2-hydroxybenzylidene)-2-(4-((3-(4-((4-fluorophenoxy)methyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)piperazin-1-yl)acetohydrazide Broader
page delivered in 0.006s